En | De
Sie sind hier: Onkologie » Urologische Tumoren 19. Oktober 2021
Urologische Tumoren
Erweiterte Suche
Kardiovaskuläre Erkrankungen
Muskuloskelettale Erkrankungen
Endokrine Organe
Gynäkologische Tumoren
Urologische Tumoren
Schrift: Schrift grösser Schrift kleiner

Rect Top
   Seite 1 von 6983  vorhergehende Seite nächste Seite
   Artikel 1 - 20 / 139643  
A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.
Int J Cancer
Payne H, Robinson A, Rappe B, Hilman S, De Giorgi U, Joniau S, Bordonaro R, Mallick S, Dourthe LM, Flores MM, Gumà J, Baron B, Duran A, Pranzo A, Serikoff A, Mott D, Herdman M, Pavesi M, De Santis M.
PMID: 34648657 [PubMed - as supplied by publisher]

Tumor necrosis factor alfa (TNFα) and alfa-Klotho (αKL) in children and adolescents with chronic kidney disease (CKD).
Endokrynol Pol
Gamrot Z, Adamczyk P, , Roszkowska-Bjanid D, Gamrot J, Szczepanska M.
PMID: 34647605 [PubMed - as supplied by publisher]

Application of Organoid Models in Prostate Cancer Research.
Front Oncol
Zhou L, Zhang C, Zhang Y, Shi C.
PMID: 34646778 [PubMed]

Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Pathol Oncol Res
Zhang C, Qian J, Wu Y, Zhu Z, Yu W, Gong Y, Li X, He Z, Zhou L.
PMID: 34646089 [PubMed - in process]

Nomogram Incorporating Contrast-Enhanced Ultrasonography Predicting Time to the Development of Castration-Resistant Prostate Cancer.
Clin Med Insights Oncol
Zhao YX, Yao GL, Sun J, Wang XL, Wang Y, Cai QQ, Kang HL, Gu LP, Yu JS, Li WM, Zhang B, Wang J, Mei JJ, Jiang Y.
PMID: 34646064 [PubMed]

Oral administration of E-type prostanoid (EP) 1 receptor antagonist suppresses carcinogenesis and development of prostate cancer via upregulation of apoptosis in an animal model.
Sci Rep
Masato M, Miyata Y, Kurata H, Ito H, Mitsunari K, Asai A, Nakamura Y, Araki K, Mukae Y, Matsuda T, Harada J, Matsuo T, Ohba K, Sakai H.
PMID: 34645904 [PubMed - in process]

Plasma lipidomic profiles of kidney, breast and prostate cancer patients differ from healthy controls.
Sci Rep
Wolrab D, Jirásko R, Peterka O, Idkowiak J, Chocholou, Va, Ho, Brabcová I, Vrána D, , Melichar B, Hol.
PMID: 34645896 [PubMed - in process]

Next-generation Proteomics-Based Discovery, Verification, and Validation of Urine Biomarkers for Bladder Cancer Diagnosis.
Cancer Res Treat
Suh J, Han D, Ku JH, Kim HH, Kwak C, Jeong CW.
PMID: 34645132 [PubMed - as supplied by publisher]

Growth Rate in Childhood and Adolescence and Risk of Breast and Prostate Cancer: A Population-Based Study.
Am J Epidemiol
Haraldsdottir A, Steingrimsdottir L, Maskarinec G, Adami HO, Aspelund T, Valdimarsdottir UA, Bjarnason R, Thorsdottir I, Halldorsson TI, Gunnarsdottir I, Tryggvadottir L, Gudnason V, Birgisdottir BE, Torfadottir JE.
PMID: 34643238 [PubMed - as supplied by publisher]

Prognostic Significance of Percentage Necrosis in Clear Cell Renal Cell Carcinoma.
Am J Clin Pathol
Syed M, Loya A, Hameed M, Akhtar N, Mushtaq S, Hassan U.
PMID: 34643216 [PubMed - as supplied by publisher]

Identification of prostate cancer specific methylation biomarkers from a multi-cancer analysis.
BMC Bioinformatics
Pu Y, Li C, Yuan H, Wang X.
PMID: 34641790 [PubMed - indexed for MEDLINE]

Effects of a Brief E-Learning Resource on Sexual Attitudes and Beliefs of Healthcare Professionals Working in Prostate Cancer Care: A Pilot Study.
Int J Environ Res Public Health
McCaughan EM, Flannagan C, Parahoo K, Bingham SL, Brady N, Connaghan J, Maguire R, Thompson S, Jain S, Kirby M, O'Connor SR.
PMID: 34639350 [PubMed - in process]

Synthetic Retinoids as Potential Therapeutics in Prostate Cancer-An Update of the Last Decade of Research: A Review.
Int J Mol Sci
Ha, , Szafra, Bohn T, Duli.
PMID: 34638876 [PubMed - in process]

Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling.
Cancers (Basel)
Xiao JF, Caliri AW, Duex JE, Theodorescu D.
PMID: 34638374 [PubMed]

Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer.
Cancers (Basel)
Ebersbach C, Beier AK, Thomas C, Erb HHH.
PMID: 34638338 [PubMed]

Proteomic Landscape of Prostate Cancer: The View Provided by Quantitative Proteomics, Integrative Analyses, and Protein Interactomes.
Cancers (Basel)
Sadeesh N, Scaravilli M, Latonen L.
PMID: 34638309 [PubMed]

Recent Advances in the Management of Patients with Non-Muscle-Invasive Bladder Cancer Using a Multidisciplinary Approach: Practical Recommendations from the Spanish Oncology Genitourinary (SOGUG) Working Group.
Cancers (Basel)
Rubio-Briones J, Algaba F, Gallardo E, Marcos-Rodríguez JA, Climent MÁ, On Behalf Of The Sogug Multidisciplinary Working Group.
PMID: 34638247 [PubMed]

Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances.
Cancers (Basel)
Movassaghi M, Chung R, Anderson CB, Stein M, Saenger Y, Faiena I.
PMID: 34638243 [PubMed]

Childhood Bladder Cancer Treatment (PDQ®): Health Professional Version

PDQ Pediatric Treatment Editorial Board, PDQ Pediatric Treatment Editorial Board.
PMID: 31846271 [PubMed]

Childhood Testicular Cancer Treatment (PDQ®): Health Professional Version

PDQ Pediatric Treatment Editorial Board, PDQ Pediatric Treatment Editorial Board.
PMID: 31846265 [PubMed]

   Artikel 1 - 20 / 139643    Seite 1 von 6983  vorhergehende Seite nächste Seite

Rect Bottom
Adserver Footer





Haben Sie Ihr Passwort vergessen?


Neu bei My Medline?

Melden Sie sich bei My Medline an!


Mehr über My Medline erfahren

mehr >>


Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.



mehr >>


Sky right 1